{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:15:23Z","timestamp":1773008123354,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s43441-025-00845-4","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T19:18:32Z","timestamp":1755631112000},"page":"92-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System Events for Tazemetostat"],"prefix":"10.1007","volume":"60","author":[{"given":"Qiong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaoqing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"5","key":"845_CR1","first-page":"513","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy SM, Tazemetostat. First Approval Drugs. 2020;80(5):513\u201321.","journal-title":"First Approval Drugs"},{"issue":"10","key":"845_CR2","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2217\/fon-2020-0781","volume":"17","author":"N Simeone","year":"2021","unstructured":"Simeone N, et al. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives. Future Oncol. 2021;17(10):1253\u201363.","journal-title":"Future Oncol"},{"issue":"11","key":"845_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder M, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21(11):1423\u201332.","journal-title":"Lancet Oncol"},{"issue":"4","key":"845_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/cge.14576","volume":"106","author":"M Sabour-Takanlou","year":"2024","unstructured":"Sabour-Takanlou M, Sabour-Takanlou L, Biray-Avci C. EZH2-associated tumor malignancy: A prominent target for cancer treatment. Clin Genet. 2024;106(4):377\u201385.","journal-title":"Clin Genet"},{"issue":"1","key":"845_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):104.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"845_CR6","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.18632\/oncotarget.2758","volume":"6","author":"AM Barsotti","year":"2015","unstructured":"Barsotti AM, et al. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth. Oncotarget. 2015;6(5):2928\u201338.","journal-title":"Oncotarget"},{"issue":"11","key":"845_CR7","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433\u201342.","journal-title":"Lancet Oncol"},{"key":"845_CR8","unstructured":"Highlights in relapsed\/refractory follicular lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition. Clin Adv Hematol Oncol. 2021. 19 Suppl 2(1): pp. 1\u201320."},{"issue":"13","key":"845_CR9","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1158\/1078-0432.CCR-19-3741","volume":"26","author":"C Sarkozy","year":"2020","unstructured":"Sarkozy C, et al. A LYSA phase Ib study of Tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma (DLBCL) with poor prognosis features. Clin Cancer Res. 2020;26(13):3145\u201353.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"845_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128\u201334.","journal-title":"Nat Med"},{"key":"845_CR11","doi-asserted-by":"crossref","unstructured":"Gilardini MM, Benedetti R, Cirone M. Targeting EZH2 in Cancer: Mechanisms, Pathways, and Therapeutic Potential. Molecules. 2024; 29(24).","DOI":"10.3390\/molecules29245817"},{"key":"845_CR12","doi-asserted-by":"publisher","first-page":"204062072110158","DOI":"10.1177\/20406207211015882","volume":"12","author":"G von Keudell","year":"2021","unstructured":"von Keudell G, Salles G. The role of Tazemetostat in relapsed\/refractory follicular lymphoma. Ther Adv Hematol. 2021;12:20406207211015882.","journal-title":"Ther Adv Hematol"},{"key":"845_CR13","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","volume":"14","author":"F Zou","year":"2023","unstructured":"Zou F, et al. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2023;14:1320458.","journal-title":"Front Pharmacol"},{"issue":"1","key":"845_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"845_CR15","doi-asserted-by":"publisher","first-page":"e70176","DOI":"10.1111\/cns.70176","volume":"30","author":"Y Xi","year":"2024","unstructured":"Xi Y, et al. Reproductive toxicity induced by Serotonin-Norepinephrine reuptake inhibitors: A pharmacovigilance analysis from 2004 to 2023 based on the FAERS database. CNS Neurosci Ther. 2024;30(12):e70176.","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"845_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40360-025-00861-y","volume":"26","author":"H Hu","year":"2025","unstructured":"Hu H, et al. The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database. BMC Pharmacol Toxicol. 2025;26(1):28.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"7","key":"845_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci"},{"key":"845_CR18","doi-asserted-by":"publisher","first-page":"204209862413034","DOI":"10.1177\/20420986241303428","volume":"15","author":"R Liu","year":"2024","unstructured":"Liu R, et al. Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database. Ther Adv Drug Saf. 2024;15:20420986241303428.","journal-title":"Ther Adv Drug Saf"},{"issue":"5","key":"845_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12185-024-03834-9","volume":"120","author":"K Izutsu","year":"2024","unstructured":"Izutsu K, et al. Tazemetostat for relapsed\/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in japan: 3-year follow-up for a phase II study. Int J Hematol. 2024;120(5):621\u201330.","journal-title":"Int J Hematol"},{"issue":"9","key":"845_CR20","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/cas.15040","volume":"112","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, et al. Phase II study of Tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 2021;112(9):3627\u201335.","journal-title":"Cancer Sci"},{"key":"845_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan L, et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10.","journal-title":"Biomark Res"},{"issue":"7","key":"845_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/chemse\/bji053","volume":"30","author":"CD Dotson","year":"2005","unstructured":"Dotson CD, Roper SD, Spector AC. PLCbeta2-independent behavioral avoidance of prototypical bitter-tasting ligands. Chem Senses. 2005;30(7):593\u2013600.","journal-title":"Chem Senses"},{"issue":"1","key":"845_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-022-01078-9","volume":"7","author":"J Park","year":"2022","unstructured":"Park J, et al. The role of histone modifications: from neurodevelopment to neurodiseases. Signal Transduct Target Ther. 2022;7(1):217.","journal-title":"Signal Transduct Target Ther"},{"key":"845_CR24","doi-asserted-by":"crossref","unstructured":"Weng HR et al. EZH2 methyltransferase regulates neuroinflammation and neuropathic pain. Cells. 2023; 12(7).","DOI":"10.3390\/cells12071058"},{"issue":"10","key":"845_CR25","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s12264-023-01074-1","volume":"39","author":"M Zhang","year":"2023","unstructured":"Zhang M, et al. Neuronal histone methyltransferase EZH2 regulates neuronal morphogenesis, synaptic plasticity, and cognitive behavior in mice. Neurosci Bull. 2023;39(10):1512\u201332.","journal-title":"Neurosci Bull"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00845-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00845-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:04:31Z","timestamp":1767150271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00845-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["845"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00845-4","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves a secondary analysis of publicly accessible summary statistics and does not necessitate explicit ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"During the preparation of this work the author(s) used DeepL in order to improve readability. After using this tool\/service, the author(s)reviewed and edited the content as needed. The author(s) take(s) full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}